Financial Performance - The company's revenue increased by 29% from $13 million in 2021 to $16.7 million in 2022[7] - Gross profit increased by 57% from $8 million in 2021 to $12.6 million in 2022[7] - Gross margin improved by 13% from 62% in 2021 to 75% in 2022[7] - Operating loss decreased by 41% from ($14.1) million in 2021 to ($8.4) million in 2022[7] - Q4 2022 revenue increased by 29% to $5.5 million compared to $4.3 million in Q4 2021[9] - Q4 2022 gross margin increased by 35% to $4.0 million compared to $2.9 million in Q4 2021[9] - Q4 2022 gross margin percentage improved by 3% to 72%[9] Unit Growth - The company experienced strong unit growth throughout 2022, reaching 220 systems[11] - The company experienced strong unit growth throughout 2022, reaching 180,300 treatments[11] Future Outlook - The company anticipates approximately 14-20% growth in Q1 2023 compared to Q1 2022[13] - The company estimates that achieving 1% market share in the US wound market would equate to $450 million[15]

Financial Performance - The company's revenue increased to $3.8 million in Q1 2023, an 18% increase year-over-year compared to $3.2 million in Q1 2022 [10] - Gross profit increased to $2.5 million in Q1 2023, a 9% increase year-over-year compared to $2.3 million in Q1 2022 [10] - Gross margin was 67% in Q1 2023, a decrease of 500 basis points compared to 72% in Q1 2022 [10] - Operating costs increased to $4.5 million in Q1 2023, a 5% increase year-over-year compared to $4.3 million in Q1 2022 [10] - The company experienced an operating loss of $2.0 million in both Q1 2022 and Q1 2023 [10] Unit Growth - The company sold 217 systems in 2022 [14] - The company sold 180,300 treatments in 2022 [14] - The company sold 28 systems as of March 31, 2023 [14] - The company sold 43,692 treatments as of March 31, 2023 [14] Future Outlook - The company estimates a 15-25% increase in Q2 2023 compared to Q2 2022 [16] - The company estimates that 1% market share in the US wound market would equal $450 million [18]

August 11, 2023 Q2 2023 Update Live Presentation Friday, August 11, 2023, 8:30 AM (EDT) Participant Dial-in Information Toll Free: 1-877-407-0784 Toll/International: 1-201-689-8560 OR click the Call me™ link for instant telephone access to the event. https://callme.viavid.com/viavid/?callme=true&passcode=13732361&h=true&info=company&r=true&B=6 Replay Dial-in Information Toll Free: 1-844-512-2921 Toll/International: 1-412-317-6671 3 Company Financials Q2 2023 Replay Pin Number: 13740603 Replay Expiry: August ...

Financial Performance - Revenue for Q3 2023 reached $5 million, a 19% increase compared to $4.2 million in Q3 2022[15] - Revenue for the nine months ended September 30, 2023, totaled $13.4 million, also a 19% increase compared to $11.2 million for the same period in 2022[15] - UltraMist consumables revenue increased by 24% to $3.1 million, constituting 62% of overall revenues in Q3 2023[15] - Net loss for the three months ended September 30, 2023, was $23.7 million, compared to a net loss of $1.1 million for the same period in 2022, primarily due to non-cash losses on the fair value of derivative liabilities[15] - Adjusted EBITDA loss for Q3 2023 was $0.3 million, an improvement of $1.9 million compared to a loss of $2.2 million in Q3 2022[15] Operational Highlights - 55 UltraMist systems were sold in Q3 2023, an increase from 28 in Q1 2023 and 49 in Q2 2023[15] - Gross margin was 71% for the three months ended September 30, 2023, slightly down from 72% in the same period last year[15] Future Outlook - The company anticipates Q4 2023 revenue will increase approximately 15% to 25% as compared to Q4 2022[17] Corporate Developments - In July 2023, the company issued Asset-Backed Secured Promissory Notes, receiving total proceeds of approximately $3 million[19] - SANUWAVE Health entered into a merger agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp in August 2023, with the combined company expected to trade on Nasdaq under the symbol "SNWV"[19]

Q4 and FY2023 March 22, 2024 Participant Dial-in Information Toll Free: 1-800-267-6316 Toll/International: 1-203-518-9783 OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1661785&tp_key=8f8d9c1839 Replay Dial-in Information Live Presentation Friday, March 22, 2024, 8:30 AM (ET) Toll Free: 1-844-512-2921 Toll/International: 1-412-317-6671 Replay Pin Number: 11155229 Replay Expiry: April 15, 2024 2 Forward Looking Statements This presentation may contai ...

Q1 FY2024 May 10, 2024 Live Presentation Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1665712&tp_key=5ceebf04ab Replay Dial-in Information Toll Free: 1-844-512-2921 Toll/International: 1-412-317-6671 Replay Pin Number: 1155590 Friday, May 10, 2024, 8:30 AM (ET) Replay Expiry: June 3, 2024 2 Forward Looking Statements This presentation may contain "forward- ...

Financial Performance - Sanuwave Health, Inc achieved record quarterly revenues of $72 million in Q2 2024, a 53% increase compared to $47 million in Q2 2023[13, 15] - Gross margin for Q2 2024 was 73%, slightly down from 74% in Q2 2023[14, 15] - GAAP Operating Income reached $20 million in Q2 2024, an improvement of $11 million from Q2 2023[14, 15] - Net income for Q2 2024 was $66 million, compared to a net loss of $73 million in Q2 2023[15] - Adjusted EBITDA for Q2 2024 was $15 million, a significant increase from $171 thousand in Q2 2023[16] Revenue Drivers - UltraMist consumables revenue increased by 67% to $47 million in Q2 2024, representing 65% of total revenues, compared to $28 million in the same quarter last year[15] - 72 UltraMist systems were sold in Q2 2024, up from 49 in Q2 2023 and 43 in Q1 2024[15] Future Outlook - The company forecasts Q3 2024 revenue to increase by 65-75% compared to Q3 2023, projecting revenues of $8-85 million[14, 17] Capital Structure - Sanuwave secured 100% participation in its note and warrant exchange offer, simplifying the company's capital structure[18]

November 8, 2024 Q3 FY2024 Participant Dial-in Information Toll Free: 1-800-267-6316 Toll/International: 1-203-518-9783 Conference ID: SANUWAVE OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1692398&tp_key=e3cff43c54 Live Presentation Friday, November 8, 2024, 8:30 AM (ET) Replay Dial-in Information Toll Free: 1-844-512-2921 Toll/International: 1-412-317-6671 Replay Pin Number: 11157276 Replay Expiry: November 29, 2024 2 Forward Looking Statements T ...

Financial Performance - Revenue for Q4 2024 reached $10.3 million, a 47% increase compared to $7.0 million in Q4 2023 [15] - Gross profit for Q4 2024 was $8.0 million, a 67% increase compared to $4.8 million in Q4 2023 [15] - Gross margin improved to 77.9% in Q4 2024, up 873 basis points from 69.1% in Q4 2023 [15] - Operating income for Q4 2024 was $2.5 million, a 150% increase compared to $1.0 million in Q4 2023 [15] - Adjusted EBITDA for Q4 2024 was $3.655 million, compared to $0.664 million in Q4 2023 [16] UltraMIST System - UltraMIST system saw continuous revenue growth with strong year-over-year growth throughout 2024 [18] - The company had 1,047 UltraMIST systems in the field at the end of Q4 2024 [20] - 135 UltraMIST systems were sold in Q4 2024, compared to 79 in Q4 2023 and 124 in Q3 2024 [20] Revenue Guidance - The company projects Q1 2025 revenue growth of 45-55% compared to Q1 2024 revenue of $5.79 million [23] - The company forecasts FY 2025 revenue of $48-50 million, representing a 47-53% increase compared to FY 2024 revenue of $32.6 million [23]

Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE Q1 FY2025 May 9, 2025 Live Presentation Friday, May 9, 2025, 8:30 AM (ET) Participant Dial-in Information OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1714486&tp_key=88406b4795 Replay Dial-in Information Toll Free: 1-844-512-2921 Toll/International: 1-412-317-6671 Replay Pin Number: 11158734 Replay Expiry: May 30, 2025 2 Forward Looking Statements and Non-GAAP Fin ...